Research groups

GC06 New Therapies in Cancer

The research group New Therapies in Cancer is multidisciplinary, with a team structure that reflects transversal capacities and skills (oncologists, biologists, pathologists, biotechnologists, etc.), and allows integrated approaches to the achievement of the proposed goals. Our aim is to conduct multifaceted research of the tumorigenic process at basic, translational, and clinical level. We participate in a National Research Network program, through the Biomedical Research Networking Center in Cancer (CIBER cancer in Spanish), and also in other cooperative groups of clinical cancer research, thus providing an excellent framework for collaboration and interaction with other cancer research groups. 

We developed several lines of study mainly aimed to address new clinical challenges in the implementation of novel targeted therapies in oncology. We conduct research in several areas of both clinical and experimental research. The first area is related to the identification of clinical or molecular factors useful in predicting clinical evolution, response or toxicity in cancer treatment. In this area we have reported the development of predictive biomarkers of response to antiangiogenic therapy.

We actively participate in the development of new therapeutic strategies using drugs aimed at specific targets. To achieve this, we are currently studying the association between antitumoral immune response and response to antiangiogenic therapy in cancer, to define predictive markers of response to antiangiogenic drugs. The development of these markers will optimize the use of new therapies in cancer patients. Another research area aims to unravel the mechanisms by which nitric oxide (NO) is involved in the onset and progression of cancer, and identify new therapeutic strategies for the treatment of this disease. Using the latest proteomic approaches to identify posttranslational nitrosative modifications, notably the S-nitrosylation of proteins, we analyze the importance of maintaining the homeostasis of nitrosothiols and the formation of S-nitrosoproteins. Results in our laboratory data support the hypothesis that the metabolism of NO plays an important role in the onset and progression of cancer, confirming a close relationship between NO and stem/mesenchymal characteristics in tumors.

Finally, our group is actively performing clinical validation studies to assess whether the determination of RAS mutational status using liquid biopsy tools may optimize the rational use of anti-EGFR therapies in colorectal cancer. Likewise, our group is applying liquid biopsy tools in other gastrointestinal tumors such as pancreatic cancers. Also, more translational studies are being undertaken in our laboratory to explore other plasma components, such as miRNAs and exosomes.

Research Lines

Networks

    CIBER on cancer CIBERONC

    PAIDI CTS-234

Keywords

  • Colorectal cancer
  • breast cancer
  • nitric oxide
  • proteomics
  • biomarkers
  • prognosis
  • prediction of response
  • liquid biopsy
  • targeted therapy
  • precision oncology

GC06 New Therapies in Cancer

Principal Investigator
Enrique Aranda Aguilar

Co-Principal Investigator
Antonio Rodríguez Ariza
Juan Rafael de la Haba Rodríguez

Researchers
Isidoro Barneto Aranda
Mª Auxiliadora Gómez España
Antonio Martínez Peinado
Carlos Villar Pastor

Post-Doctoral Researchers
Silvia Guil Luna
Laura María López Sánchez
Cristina Morales Estévez
Manuel Jesús Valladares Ayerbes

Clinical Researchers
Mª Teresa Cano Osuna
Elena Fuentes Vaamonde
Mª José Méndez Vidal
Alberto Luis Moreno Vega
Ignacio Porras Quintela
Beatriz Rodríguez Alonso
Rosa Mª Rodríguez Alonso
Pedro Sánchez Mauriño
Raquel Serrano Blanch

Pre-Doctoral Researchers
Rafael Mena Osuna
Mª José Ortiz Morales
Marta del Pilar Toledano Fonseca

Technical and Administrative Staff
Asunción Aranda Aguilar
Daniel José Campón Montilla
Mª Ángeles Diaz Diaz
Cristina Elias López
Isabel Jaraba Mezquida
Amalia Leña Barranco
María López García
Jacinta Marín Serrano
Mª Jose Marín Serrano
Mª Pilar Mesa Blanco
Rosario Miranda García
Rebeca Pavón Gómez
Sonia Rodríguez Rodríguez de Julián

Projects

Active Projects

Local

Aranda Aguilar, E. Genetic variations associated with hypertension and thrombosis as predictors of response to antiangiogenic therapy in patients with colon cancer. Funding agency: Asociación española contra el cancer. Reference: AECC14/002

Regional

Guil Luna, S. Antitumor effect of immunotherapy by blocking pd-1 combined with antiangiogenic therapy in humanized murine models of colorectal cancer. Funding agency: Regional Ministry of Health and Social Policy (CISPS). Reference: PI-0150-2017

Guil Luna, S. Caracterización del microambiente inmune tumoral en cáncer colorectal y de mama y determinación de biomarcadores con terapia dirigida; Funding Agency: FIBICO. FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA; Reference: EF-0239-2018-FIB

National

De la Haba JR. Epigenetic profile in cancer patients with increased blood pressure secondary to anti-VEGF treatment. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI15/00516

Aranda Aguilar, E. The association among anti-tumor immunity, the renin-angiotensin system and response to antiangiogenic therapy in colorectal cancer. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI16/01271 

Rodríguez Ariza, A. Relationships between nitric oxide and molecular subtypes in colorectal cancer: identification of new therapeutic strategies. Funding agency: National Institute of Health Carlos III (ISCIII). Reference:  PI16/01508

Aranda Aguilar, E. CIBER-OBN. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: CB16/12/00349

De la Haba JR. Caracterización molecular del cáncer de mama gestacional..Funding Agency: National Institute of Health Carlos III (ISCIII).Reference:PI18/00817

Morales Estévez, C. Análisis de la combinación in vitro de trastuzumab y lirilumab en cáncer de mama. Implicación de los procesos de splicing alternativo.Funding Agency: sociedad española de oncología médica.Reference:SEOM18/01

Publications

Publications 2019

Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S. Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 2019. 63. 9. DOI:10.1002/mnfr.201800864.
IF: 5,151
D: 1

Penarando J, Aranda E, Rodriguez-Ariza A. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response. TRANSLATIONAL RESEARCH. 2019. 210. 99-108. DOI:10.1016/j.trs1.2019.03.003.
IF: 4,915
D: 1

Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. BRITISH JOURNAL OF CANCER. 2019. 121. 5. 378-383. DOI:10.1038/s41416-019-0537-z.
IF: 5,416
Q: 1

Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. . 0. DOI:10.1111/jcmm.14693.
IF: 4,658
Q: 1

Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC CANCER. 2019. 19. DOI:10.1186/s12885-019-5753-7.
IF: 2,933
Q: 3

Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 2019. 21. 1. 46-54. DOI:10.1007/s12094-018-02002-w.
IF: 2,441
Q: 3

Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J. Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 2019. 19. 11. 1388-1398. DOI:10.2174/1871520619666190417162409.
IF: 2,18
Q: 3

Ciruelos E, Perez-Garcia JM, Gavila J, Rodriguez A, de la Haba-Rodriguez J. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. CLINICAL DRUG INVESTIGATION. 2019. 39. 7. 595-606. DOI:10.1007/s40261-019-00790-9.
IF: 1,918
Q: 3

Main Publications 2018

Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. ANNALS OF ONCOLOGY. 2018; 29(2):439-444.
IF: 13,926  
Q: 1   D: 1

Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC BIOLOGY. 2018; 16:Núm artículo 3
IF: 5,77  
Q: 1   D: 1

Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Teijido PG, Viudez A, Cardenas N, Diaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. EUROPEAN JOURNAL OF CANCER. 2018; 101:263-272.
IF: 7,191  
Q: 1

Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ONCOLOGIST. 2018; 23(11):1271-e128.
IF: 5,306  
Q: 1

Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Tabernero J, Giralt J, Aranda E. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. TARGETED ONCOLOGY. 2018; 13(1):69-78.
IF: 3,877  
Q: 2

Other Publications 2018

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology. TRENDS IN IMMUNOLOGY. 2018; 39(9):748-763.
IF: 14,188  
Q: 1   D: 1

Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limon ML, Safont MJ, de Castro EM, Garcia-Alfonso P, Aranda E. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2018; 17(2):E323-E329.
IF: 3,861  
Q: 2

Munoz AP, Garcia JMC, Rubio MDT, Vicente AMG, Pardo FJP, Londono GAJ, Castrejon AS, Aguilar EA. Value of [F-18]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages. MEDICINE; 2018:97(17):Núm  artículo e0098
IF: 2,028  
Q: 2

Mendez-Vidal MJ, Molina A, Anido U, Chirivella I, Etxaniz O, Fernandez-Parra E, Guix M, Hernandez C, Lambea J, Montesa A, Pinto A, Ros S, Gallardo E. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC PHARMACOLOGY & TOXICOLOGY. 2018; 19:Núm artículo 77
IF: 1,865  
Q: 3

Munoz AP, Garcia JMC, Rubio PT, Vicente AMG, Garcia BG, Guardia MEB, Castrejon AS, Aguilard EA. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG) in the detection of recurrent ovarian cancer. MEDICINA CLINICA. 2018; 151(3):97-102.
IF: 1,168  
Q: 3 

Lopez RL, Herrero CC, Khosravi-Shahi P, Porta VG, Mena AC, Garcia-Foncillas J, Hernandez JJC, Vilaplana PG, Torres AA, Diaz-Rubio E, Saus MF, Aguilar EA. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(5):613-618.
IF: 2,392   
Q: 3

Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(28):2826-2835.
IF: 26,303  
Q: 1   D: 1

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Zalcberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018; 110(6):638-648.
IF: 11,238  
Q: 1   D: 1

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 103:205-213.
IF: 7,191  
Q: 1

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 91:99-106.
IF: 7,191  
Q: 1

Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muinelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER. 2018; 119(12):1464-1470.
IF: 5,922  
Q: 1

Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuno FM, Guillen-Ponce C, Rojas I, Arande E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLOS ONE. 2018; 13(4):Núm artículo e0194844
IF:  2,766  
Q: 1

Arriola E, Gomez RG, Diz P, Majem M, Aguillo MM, Valdivia J, Paredes A, Sanchez-Torres JM, Munoz SP, Barneto I, Gutierrez V, Santiago JMA, Aparisi F, Isla D, Ponce S, Baz DV, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC CANCER 2018; 18:Núm artículo 106
IF: 3,288  
Q: 2

Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC CANCER. 2018; 18:Núm artículo 183
IF: 3,288  
Q: 2

Castellano D, Maroto JP, Espinosa E, Grande E, Bolos MV, Llinares J, Esteban E, del Alba AG, Climent MA, Arranz JA, Mendez MJ, Parra EF, Anton-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, Donas JG. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. EXPERT OPINION ON DRUG SAFETY. 2018; 17(6):573-579.
IF: 3,156  
Q: 2

Caries J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, del Alba AG, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. CLINICAL GENITOURINARY CANCER. 2018; 16(6):E1133-E1139.
IF: 2,539  
Q: 2

Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cadenas-Rebollo JM, Garcia-Garcia A, Gil-Ibanez B, Juan-Fita MJ, Patrono MG. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(10):1337-1344.
IF: 2,392  
Q: 3

Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, Garcia-del-Muro X, Gonzalez-Del-Alba A, Grande E, Suarez C. SEOM clinical guideline for treatment of kidney cancer (2017). CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(1):47-56.
IF: 2,392  
Q: 3

Carles J, Mendez MJ, Pinto A, Saez MI, Arranz JA, Maroto P, Lopez-Criado P, Mellado B, Donas JG, Hernando S, Leon L, del Alba AG, Lainez N, Esteban E, Reynes G, Perez-Gracia JL, Germa JR, Lopez-Brea M, Perez-Valderrama B, Moretones C, Castellano D. Radium-223 international early access program: results from the Spanish subset. FUTURE ONCOLOGY. 2018; 14(1):41-50.
IF: 2,369  
Q: 3

Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV. Post-colonoscopy colorectal cancer: Characteristics and predictive factors. MEDICINA CLINICA. 2018; 150(1):1-7.
IF: 1,168  
Q: 3

Main Publications 2017

Irigoyen A, Gallego J, Ponce CG, Vera R, Iranzo V, Ales I, Areevalo S, Pisa A, Martin M, Salud A, Falco E, Saenz A, Mozo JLM, Pulido G, Galaan JM, Pazo-Cid R, Rivera F, Garcia TG, Serra O, Parra EMF, Hurtado A, Reina MJG, Gomez LJL, Esther MOW, Benavides M, Aranda E, Spanish Cooperative Grp Treatment. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. EUROPEAN JOURNAL OF CANCER. 2017.7:73-82.
IF: 6,029
Q: 1 

Valverde A, Penarando J, Canas A, Lopez-Sanchez LM, Conde F, Guil-Luna S, Hernandez V, Villar C, Morales-Estevez C, de la Haba-Rodriguez J, Aranda E, Rodriguez-Ariza A. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-beta-catenin signaling axis. ONCOTARGET. 2017.8(13):21754-21769.
IF: 5,168
Q: 1 

Luque RM, Lopez-Sanchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM, Cara-Garcia M, Alvarez-Benito M, Lopez-Miranda J, Gahete MD, Castano JP. Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. ONCOTARGET. 2017.8(46):81462-81474.
IF: 5,168
Q: 1 

Lopez-Sanchez LM, Jurado-Gamez B, Feu-Collado N, Valverde A, Canas A, Fernandez-Rueda JL, Aranda E, Rodriguez-Ariza A. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY. 2017.313(4):L664-L676.
IF: 4,281
Q: 1 

Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de las Mulas JM, Millan-Ruiz Y, Guil-Luna S. Demethylating and anti-hepatocarcinogenic potential of hesperidin, a natural polyphenol of Citrus juices. MOLECULAR CARCINOGENESIS. 2017.56(6):1653-1662.                    
IF: 4,185
Q: 2 

Lopez-Vivanco G, Salvador J, Diez R, Lopez D, De Salas-Cansado M, Navarro B, De la Haba-Rodriguez J. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017.19(12):1454-1461.
IF: 2,353
Q: 3 

Aranda E, Aparicio J, Bilbao JI, Alfonso PG, Maurel J, Rodriguez J, Sangro B, Vieitez JM, Feliu J. Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. FUTURE ONCOLOGY. 2017.13(23):2065-2082.
IF: 2,131
Q: 3 

Perez MJR. Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer. CASE REPORTS IN ONCOLOGY. 2017.10(2):433-437.
IF: n/a

Other Publications 2017

Grasselli J, Elez E, Caratu G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Vieitez JM, Paez D, Falco E, Lopez CL, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. ANNALS OF ONCOLOGY. 2017.28(6):1294-1301.
IF: 11,855
Q: 1  D: 1

Garcia-Foncillas J, Alba E, Aranda E, Diaz-Rubio E, Lopez-Lopez R, Tabernero J, Vivancos A. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. ANNALS OF ONCOLOGY. 2017.28(12):2943-2949.
IF: 11,855
Q: 1  D:1

Sartor O, Heinrich D, Mariados N, Vidal MJM, Keizman D, Karlsson CT, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Perez JMT, Wagner V, Li R, Nordquist LT. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. ANNALS OF ONCOLOGY. 2017.28(10):2464-2471.
IF: 11,855
Q: 1  D: 1

Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, del Alba AG, Mellado B, Fernandez-Calvo O, Mendez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Saez MI, Puente J, Tandefelt DG, Wingate A, Dearnaley D, PREMIERE Collaborators; Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. ANNALS OF ONCOLOGY. 2017.28(7):1508-1516.
IF: 11,855
Q: 1  D: 1

Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodriguez J, Arcusa A, Chacon JI, Sanchez-Rovira P, Plazaola A, Munoz M, Pare L, Parker JS, Ribelles N, Jimenez B, Bin Aiderus AA, Caballero R, Adamo B, Dowsett M, Carrasco E, Martin M, Dixon JM, Perou CM, Alba E. A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. CLINICAL CANCER RESEARCH. 2017.23(12):3035-3044.
IF: 9,619
Q: 1  D: 1

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Jimenez-Gomez Y, Arias-de la Rosa I, Abalos-Aguilera MC, Rodriguez-Ariza A, Castro-Villegas MC, Ortega-Castro R, Segui R, Martinez C, Gonzalez-Conejero R, Rodriguez-Lopez S, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Escudero A, Barbarroja N, Lopez-Pedrera C. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. JOURNAL OF AUTOIMMUNITY. 2017.82():31-40.
IF: 7,641
Q: 1  D: 1

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. MOLECULAR CANCER THERAPEUTICS. 2017.16(9):1999-2007.
IF: 7,564
Q: 1 

Carrato A, Abad A, Massuti B, Gravalos C, Escudero P, Longo-Munoz F, Manzano JL, Gomez A, Safont MJ, Gallego J, Garcia-Paredes B, Pericay C, Duenas R, Rivera F, Losa F, Valladares-Ayerbes M, Gonalez E, Aranda E, Spanish Cooperative Grp Treatment. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). EUROPEAN JOURNAL OF CANCER. 2017.81:191-202.
IF: 6,029
Q: 1  D: 1

Perez-Sanchez C, Aguirre MA, Ruiz-Limon P, Abalos-Aguilera MC, Jimenez-Gomez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernandez-del Rio L, Gonzalez-Reyes JA, Segui P, Collantes-Estevez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, Lopez-Pedrera C. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile A Randomized, Placebo-Controlled Trial.ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2017.37(10):1923-1932.
IF: 6,607
Q: 1  D: 1

Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, Gonzalez-Rivera M, Galvan P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Pare L, Alonso I, Albanell J, Vivancos A, Gonzalez A, Matito J, Gonzalez S, Fernandez P, Adamo B, Munoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. ONCOTARGET. 2017.8(13):21930-21937.
IF: 5,168
Q: 1 

Puente J, Lainez N, Duenas M, Mendez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernandez M, Basterretxea L, Juan-Fita MJ, Anton L, Leon L, Lambea J, Perez-Valderrama B, Vazquez S, Suarez C, del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suarez-Paniagua B, Sanz J, Paramio JM, SOGUG (Spanish Oncology Genitourinary Group). Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. ONCOTARGET. 2017.8(18):30410-30421.
IF: 5,168
Q: 1 

del Alba AG, Arranz JA, Puente J, Mendez-Vidal MJ, Gallardo E, Grande E, Perez-Valderrama B, Gonzalez-Billalabeitia E, Lazaro-Quintela M, Pinto A, Lainez N, Piulats JM, Esteban E, Rey JPM, Garcia JA, Suarez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017.113:171-190.
IF: 4,971
Q: 1 

Cebrian A, del Pulgar TG, Mendez-Vidal MJ, Gonzalvez ML, Lainez N, Castellano D, Garcia-Carbonero I, Esteban E, Saez MI, Villatoro R, Suarez C, Carrato A, Munarriz-Ferrandiz J, Basterrechea L, Garcia-Alonso M, Gonzalez-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, del Alba AG, Moreno F, Reynes G, Rodriguez-Remirez M, Boni V, Mahillo-Fernandez I, Martin Y, Viqueira A, Garcia-Foncillas J. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. SCIENTIFIC REPORTS. 2017.7-41371.
IF: 4,259
Q: 1 

Capdevila J, Trigo JM, Aller J, Manzano JL, Adrin SG, Llopis CZ, Reig O, Bohn U, Cajal TRY, Duran-Poveda M, Astorga BG, Lopez-Alfonso A, Martinez JM, Porras I, Reina JJ, Palacios N, Grande E, Cillan E, Matos I, Grau JJ. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2017.177(4):309-317.
IF: 4,101
Q: 1 

Braga S, Cardoso J, Andre S, Brito M, Sanchez P, Orvalho L, Salgado L, Dias S, Pereira-Leal JB, Passos-Coelho JL. Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer? CURRENT CANCER DRUG TARGETS. 2017.17(1):62-73.
IF: 2,992
Q: 3 

Maroto P, Esteban E, Parra EF, Mendez-Vidal MJ, Domenech M, Perez-Valderrama B, Calderero V, Perez-Gracia JL, Grande E, Algaba F. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. ONCOTARGETS AND THERAPY. 2017.10:4635-4642.
IF: 2,612
Q: 2 

Gonzalez A, Lluch A, Aba E, Albanell J, Anton A, Alvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortes J, de la Haba J, Lopez-Vega JM, Martinez E, Munoz M, Pelaez I, Redondo A, Rodriguez A, Rodriguez CA, Ruiz A, Llombart A. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). CLINICAL & TRANSLATIONAL ONCOLOGY. 2017.19(5):616-624.
IF: 2,353
Q: 3 

Perez-Segura P, Palacio JE, Vazquez L, Monereo S, de las Penas R, de Icaya PM, Gravalos C, Lecube A, Blasco A, Garcia-Almeida JM, Barneto I, Goday A. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017.19(6):682-694.
IF: 2,353
Q: 3 

Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO OPEN. 2017.2(3):-UNSP e000187.
IF: n/a

Garcia-Cabezas S, Centeno-Haro M, Espejo-Perez S, Carmona-Asenjo E, Moreno-Vega AL, Ortega-Salas R, Palacios-Eito A. Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case. WORLD JOURNAL OF CLINICAL ONCOLOGY. 2017.8(4):366-370.
IF: n/a

Clinical Research

Active in 2019

An open, multicenter, randomized, phase III study of lapatinib, trastuzumab sequentially administered or administered in combination as adjuvant treatment in a patient with HER2/ERbB2-positive breast cancer.
PI: Dr. Juan Rafael de la Haba Rodríguez

A multicenter, randomized, double-blind, placebo-controlled study to compare chemotherapy plus trastuzumab and placebo versus chemotherapy plus trastuzumab and pertuzumab as adjuvant treatment in HER-2 positive primary breast cancer patients.
PI: Dr. Juan Rafael de la Haba Rodríguez

A multicenter, randomized, double-blind, placebo-controlled, phase III trial to assess the efficacy and safety of pertuzumab in combination with to assess the efficacy of trastuzumab and chemotherapy in patients with HER2-positive gastric and gastroesophageal junction cancer.
PI: Dr. Enrique Aranda Aguilar

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer ETNA (Evaluating Treatment With Neoadjuvant Abraxane)
PI: Dr. Juan Rafael de la Haba Rodríguez

A multicenter, randomized, double-blind, placebo-controlled, phase III study of maintenance therapy with Olaparib alone in patients with BRCA-positive ovarian cancer or with platinum-sensitive relapsed ovarian cancer with complete response, or patients with EGFR activating mutations.
PI: Dr. Mª Jesús Rubio Pérez

A multicenter, randomized, double-blind, placebo-controlled, phase III study of maintenance therapy with Olaparib alone in patients with FIGO stage IIIb-IV ovarian cancer with complete or partial response after platinum-based first-line chemotherapy.
PI: Dr. Mª Jesús Rubio Pérez

Abirateriona acetate maintenance in combination with docetaxel after disease progression to abiraterona acetate in metastatic castration resistant prostate cancer. Randomized phase II study.
PI: Dr. Mª José Méndez Vidal

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse.
PI: Dr. Mª José Méndez Vidal

Phase III, international, randomized trial of more pegylated doxorubicin liposomal trabedectine (DLP) compared to carboplatin plus DLP in patients with ovarian cancer who have experienced progression in the last 6-12 months following treatment.
PI: Dr. Mª Jesús Rubio Pérez

A phase III study to assess the efficacy of palbociclib (PD-0332991), a cyclin-dependent kinase 4/6 inhibitor in patients with primary HR positive breast cancer and normal HER2 at high risk of relapse following chemotherapy.
PI: Dr. Juan Rafael de la Haba Rodríguez

A multinational, multicenter, phase II study to assess the efficacy of pertuzumab plus trastuzumab and neoadjuvant chemotherapy based on anthracyclines in patients with locally advanced, inflammatory or early positive her2 breast cancer.
PI: Dr. Juan Rafael de la Haba Rodríguez

A multicenter, randomized, placebo-controlled, parallel-group phase III study to assess the efficacy and safety of olaparib as neoadjuvant treatment in patients with high-risk HER2 negative breast cancer.
PI: Dr. Juan Rafael de la Haba Rodríguez

Assessing an immunomodulatory maintenance therapy in patients with metastatic colorectal cancer with tumor shrinkage during induction therapy. A phase III trial.
PI: Dr. Enrique Aranda Aguilar

A randomized, open-label, phase III study to assess the effectiveness of including denosumab in standard first-line chemotherapy for advanced small cell lung cancer.
PI: Dr. Isidoro Barneto Aranda

A multinational randomised, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer.
PI: Dr. Mª José Méndez Vidal

Phase II multicenter study that analyzes the predictive value of response to ENZALUTAMIDE fusion gene TMPRSS2 -ETS in patients with metastatic CRPC previously treated with chemotherapy.
PI: Dr. Mª José Méndez Vidal

Phase II randomized double-blind study comparing treatment every 3 weeks with carboplatin (AUC 5) + 175 mg / m2 of paclitaxel, with or without concomitant nintedanib and maintenance in advanced or recurrent cervical carcinoma.
PI: Dr. Mª Jesús Rubio Pérez

Phase III study, open, multicenter, randomized trial to investigate the efficacy and safety of mpdl3280a (anti-pd-l1) compared to chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after fault based regime platinum chemotherapy.
PI: Dr. Mª José Méndez Vidal

Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI and against lapatinib plus an AI as first or second line therapy in postmenopausal patients with cancer metastatic breast cancer (MBC) HER2 positive and hormone receptor-positive who have received prior treatment with trastuzumab and endocrine therapy
PI: Dr. Juan Rafael de la Haba Rodríguez

Multicenter, open single-arm safety study of herceptin s.c. in combination with docetaxel PERJETA and in the treatment of patients with advanced HER2 positive (metastatic or locally recurrent) breast cancer.
PI: Dr. Juan Rafael de la Haba Rodríguez

A phase III, open-label, randomized study of MPDL3280a (anti-PDL1 antibody) in combination with Carboplatin - Paclitaxel with or without Bevacizumab compared with Carboplatin – Paclitaxel - Bevacizumab in chemotherapy naive patients with stage IV nonsquamous non-small cell lung cancer.
PI: Dr. Isidoro Barneto Aranda

A phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) in combination with Carboplatin - Paclitaxel or MPDL3280A in combination with Carboplatin- Nab Paclitaxel versus Carboplatin – Nab-Paclitaxel in chemotherapy naive patients with stage IV squamous non-small cell lung cancer.
PI: Dr. Isidoro Barneto Aranda

Multicenter open-label study, randomized controlled phase III to assess the efficacy and safety of olaparib monotherapy versus chemotherapy with single agent lesson by her doctor in the treatment of ovarian cancer relapsed platinum-sensitive in patients carrying germline mutations BRCA1 /2.
PI: Dr. Mª Jesús Rubio Pérez

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5- Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
PI: Dr. Enrique Aranda Aguilar

Phase II, multicenter, randomized, double-blind, parallel group study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500 mg with placebo and Fulvestrant (FaslodexTM) 500 mg in combination with PD-0332991 (Palbociclib) as first-line treatment for postmenopausal patients with metastatic breast cancer and hormone receptor positive. FLIPPER study.
PI: Dr. Juan Rafael de la Haba Rodríguez

Phase III randomized trial with the monoclonal anti-PD-1 pembrolizumab (MK-3475) antibody compared to placebo in patients with NSCLC in early stages after resection and completion of adjuvant treatment reference (PEARLS).
PI: Dr. Isidoro Barneto Aranda

Randomised phase II study comparing, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with advanced breast cancer. TempoBreast 1.
PI: Dr. Juan Rafael de la Haba Rodríguez

Multicenter randomized clinical trial on maintenance of treatment based on biomarkers for first line metastatic colorectal cancer (modul).
PI: Dr. Enrique Aranda Aguilar

Phase II study with preoperative MPDL3280A in operable transitional cell carcinoma of the bladder (ABACUS).
PI: Dr. Mª José Méndez Vidal

An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy.
PI: Dr. Enrique Aranda Aguilar

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
PI: Dr. Juan Rafael de la Haba Rodríguez

Ensayo clínico multicéntrico fase III, randomizado para la comparación de epirubicina.
PI: Dr. Enrique Aranda Aguilar

Ensayo aleatorizado, en doble ciego y controlado con placebo, de neratinib (HKI-272) después de trastuzumab en mujeres con cáncer de mama en estadío inicial con sobreexposición/amplificación de HER-2/neu.
PI: Dr. Juan Rafael de la Haba Rodríguez

Estudio fase III aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de pazopanib como tratamiento adyuvante en sujetos con carcinoma de células renales localizado o localmente avanzado tras nefrectomía.
PI: Dr. Mª José Méndez Vidal

Estudio fase IV.III multicéntrico, abierto, de asignación aleatoria de tratamiento, para evaluar la eficacia de terapia de mantenimiento con capecitqabina (X) tras quimioterapia adyuvante estándar en pacientes con cáncer de mama operable, receptores hormo.
PI: Dr. Juan Rafael de la Haba Rodríguez

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma.
PI: Dr. Mª José Méndez Vidal

Estudio fase II para evaluar la eficacia del retratamiento con Sunitinib en pacientes con tumores neuroendócrinos pancreáticos bien diferenciados G1/2 (pNET) avanzados o metastásicos que ya han fracasado a un tratamiento  con Sunitinib previo (Estudio RESUNET).
PI: Dr. Raquel Serrano Blanch

A Randomized Phase 2 Study Comparing Different Dose Approaches of Induction Treatment (First Cycle) of Regorafenib in Metastatic Colorectal Cancer (mCRC) Patients.
PI: Dr. Enrique Aranda Aguilar

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer.
PI: Dr. Enrique Aranda Aguilar

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy (KATE2).
PI: Dr. Juan Rafael de la Haba Rodríguez

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial).
PI: Dr. Isidoro Barneto Aranda

A Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms.
PI: Dr. Mª Auxiliadora Gómez España

A randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin in 1st line treatment for patients with Advanced/Recurrent Non-Squamous non-small cell lung cancer in combination of paclitaxel and carboplatin.
PI: Dr. Isidoro Barneto Aranda

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma.
PI: Dr. Enrique Aranda Aguilar

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract.
PI: Dr. Mª José Méndez Vidal

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy.
PI: Dr. Mª José Méndez Vidal

Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months.
PI: Dr. Isidoro Barneto Aranda

A Randomized, Double-blind, Placebo Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer.
PI: Dr. Mª José Méndez Vidal

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma.
PI: Dr. Mª José Méndez Vidal

A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) PANGEA-Breast.
PI: Dr. Juan Rafael de la Haba Rodríguez

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS).
PI: Dr. Mª Teresa Cano Osuna

A Phase II Clinical Trial to Analyse Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast Study).
PI: Dr. Juan Rafael de la Haba Rodríguez

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma.
PI: Dr. Mª José Méndez Vidal

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer.
PI: Dr. Mª José Ortiz Morales

Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study).
PI: Dr. Mª José Méndez Vidal

Estudio de fase III, aleatorizado y doble ciego para evaluar pembrolizumab más quimioterapia frente a un placebo más quimioterapia como tratamiento neoadyuvante y pembrolizumab frente a un placebo como tratamiento adyuvante para el cáncer de mama triple.
PI: Dr. Juan Rafael de la Haba Rodríguez

COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
PI: Dr. Juan Rafael de la Haba Rodríguez

A Multicentre, International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer Patients (BioPER).
PI: Dr. Juan Rafael de la Haba Rodríguez

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer.
PI: Dr. Mª José Méndez Vidal

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV.
PI: Dr. Mª Jesús Rubio Pérez

Trastuzumab y pertuzumab sin quimioterapia en cancer de mama HER+: estrategia adaptada en funcion de la respuesta evaluada por FDG-PET. Estudio PHERGain.
PI: Dr. Juan Rafael de la Haba Rodríguez

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer.
PI: Dr. Juan Rafael de la Haba Rodríguez

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma.
PI: Dr. Mª Teresa Cano Osuna

A Randomized, Double-blind, Placebo-controlled, Phase II Trial of Palbociclib in Combination With Letrozole Versus Placebo in Combination With Letrozole for Patients With Estrogen Receptor Positive Advanced or Recurrent Endometrial Cancer.
PI: Dr. Mª Jesús Rubio Pérez

Randomised, Multicentre, Phase II Pilot Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With Metastatic Colorectal Cancer (mCRC) After Failure of an Oxaliplatin-based Regimen.
PI: Dr. Mª Auxiliadora Gómez España

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer.
PI: Dr. Juan Rafael de la Haba Rodríguez

A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer.
PI: Dr. Isidoro Barneto Aranda

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.
PI: Dr. Mª Jesús Rubio Pérez

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer.
PI: Dr. Isidoro Barneto Aranda

A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment.
PI: Dr. Mª José Méndez Vidal

A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL).
PI: Dr. Isidoro Barneto Aranda

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies&.
PI: Dr. Alberto Luis Moreno Vega

Estudio fase III multicéntrico, randomizado, con Atezolizumab (anticuerpo anti pd- l1) en combinación con Enzalutamida frente a Enzalutamida sola en pacientes con cáncer de próstata resistente a la castración tras fallo de un inihibidor de la síntesis de andrógenos y fallo o no elegible o rechazo de tratamiento con Taxanos.
PI: Dr. Mª José Méndez Vidal

ME-344 en cáncer de mama HER2-negativo en estadio temprano con metabolismo mitocondrial inducido con antiangiogénicos: ensayo fase 0.
PI: Dr. Juan Rafael de la Haba Rodríguez

Estudio de largo seguimiento de pacientes con cáncer de mama incluidos en estudios en estadios precoces del grupo GEICAM.
PI: Dr. Juan Rafael de la Haba Rodríguez 

A phase II, Multicentric, Open, Controlled and Randomized, to assess the efficacy of the intra arterial infusion of mononuclear cells of autologous bone marrow in patients with ischemic stroke.
PI: Dr. Mª José Méndez Vidal

Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo, de Pembrolizumab (MK-3475) en combinación con Cisplatino y 5-Fluorouracilo en comparación con Placebo en combinación con Cisplatino y 5-Fluorouracilo como tratamiento de primera línea en sujetos con carcinoma de esófago avanzado o metastásico (KEYNOTE-590).
PI: Dr. Mª Teresa Cano Osuna

Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre Avelumab* (MSB 0010718c) más los mejores cuidados paliativos frente a los mejores cuidados paliativos solos como tratamiento de mantenimiento en pacientes con cáncer urotelial localmente avanzado o mestastásico sin progresión de la enfermedad tras completar la quimioterapia de primera línea basada en platino.
PI: Dr. Mª José Méndez Vidal

OPINIÓN - Estudio en fase IIIb, abierto, de grupo único y multicéntrico de la monoterapia de mantenimiento con Olaparib en pacientes con cáncer de ovario recidivante sin mutación de BRCA en línea germinal y sensible al platino que están en respuesta parcial o completa tras la quimioterapia con platino.
PI: Dr. Mª Jesús Rubio Pérez

Phase II clinical trial of enzalutamide in advanced unresectable or metastatic ovarian granulosa cancer. GreKo III STUDY.
PI: Dr. Mª Jesús Rubio Pérez

Estudio de fase 2 de Prexasertib en cáncer de ovario resistente o recurrente refractario a derivados del platino.
PI: Dr. Mª Jesús Rubio Pérez

Estudio abierto, aleatorizado, fase 3 comparando trifluridina/tipiracilo (S95005) en combinación con bevacizumab y capecitabina en combinación con bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candi.
PI: Dr. Mª José Ortiz Morales

Estudio de fase 2/3 aleatorizado, abierto, multicéntrico para evaluar la eficacia y seguridad de Rogaratinib (BAY 1163877) comparado con quimioterapia en pacientes FGFR positivos con carcinoma urotelial metastásico o localmente avanzado que hayan recibido previamente quimioterapia con platino.
PI: Dr. Mª José Méndez Vidal

Estudio en fase III sobre erdafitinib en comparación con vinflunina, docetaxel o pembrolizumab en sujetos con carcinoma urotelial avanzado y anomalías genéticas seleccionadas en FGFR.
PI: Dr. Mª José Méndez Vidal

Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, que evalúa la eficacia y seguridad de canakinumab frente a placebo como terapia adyuvante en pacientes adultos con cáncer de pulmón no microcítico (NSCLC) completamente resecado (R0), en estadío II-IIIA y IIIB (T>5 cm N2) según el AJCC/UICC v.8.
PI: Dr. Isidoro Barneto Aranda

Estudio de fase II en el que se investiga la combinación de estrategias preoperatorias en la inmunoterapia de pacientes con cáncer de mama primario, ER positivo, HER2 negativo, no tratado y operable (ECLIPSE).
PI: Dr. Juan Rafael de la Haba Rodríguez

Estudio en fase III multicéntrico, abierto, randomizado, con dos brazos de tratamiento, para evaluar la farmacocinética, la eficacia y la seguridad de la administración subcutánea de la combinación en dosis fijas de Pertuzumab y Trastuzumab en combinación con quimioterapia en  acientes con cáncer de mama precoz HER2 positivo.
PI: Dr. Igancio Porras Quintela

Estudio de extensión y observacional a largo plazo multicéntrico, abierto en pacientes incluidos previamente en un estudio clínico de atezolizumab promocionado por Genentech y/o F. Hoffmann - La Roche Ltd.
PI: Dr. Mª José Méndez Vidal

Estudio de fase 3, abierto y aleatorizado, para evaluar enfortumab vedotina en comparación con quimioterapia, en sujetos con cáncer urotelial localmente avanzado o metastásico ya tratado previamente (EV-301).
PI: Dr. Mª José Méndez Vidal

Estudio aleatorizado fase III de quimioterapia con platino y Paclitaxel mas Bevacizumab y Atezolizumab frente a quimioterapia con platino y Paclitaxel mas Bevacizumab en carcinoma de cérvix metastásico (estadio IVB), persistente o recurrente.
PI: Dr. Mª Jesús Rubio Pérez

Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de FOLFOX + Panitumumab seguido por FOLFIRI + Bevacizumab (Secuencia 1) frente a FOLFOX + Bevacizumab seguido por FOLFIRI + Panitumumab (Secuencia 2) en pacientes con cáncer colorrectal metastásico no resecable, RAS nativo, tumor primario en lado izquierdo, no tratado previamente: CR-SEQUENCE.
PI: Dr. Mª Auxiliadora Gómez España

Ensayo fase III, aleatorizado y doble ciego de quimioterapia basada en platino con o sin Atezolizumab, seguida de mantenimiento con Niraparib con o sin Atezolizumab, en pacientes con cáncer de ovario, de trompa de falopio o peritoneal recidivante e intervalo libre de tratamiento con platino (ILP) >6 meses. (ANITA).
PI: Dr. Mª Jesús Rubio Pérez

Ensayo  clínico  aleatorizado,  fase  II/III,  con  múltiples  brazos  y  multietapa,  de  estrategias de inmunoterapia en cáncer de próstata metastásico sensible a hormonas.
PI: Dr. Mª José Méndez Vidal

Estudio fase 3, aleatorizado, abierto, de NKTR-214 en combinación con nivolumab frente a nivolumab en pacientes con melanoma irresecable o metastásico previamente no tratado.
PI: Dr. Pedro Sánchez Mauriño

Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de Ipatasertib en combinación con Paclitaxel para el tratamiento de pacientes con cáncer de mama triple negativo o cáncer de mama positivo para receptores hormonales y negativo para her2, en ambos casos localmente avanzado o metastásico y con alteración de PIK3CA/AKT1/PTEN.
PI: Dr. Juan Rafael de la Haba Rodríguez

Eficacia de olaparib en combinación con trastuzumab en pacientes con cáncer de mama avanzado HER2-positivo, y con mutación en BRCA o Deficiencia en la Recombinación Homóloga (DRH) - Estudio OPHELIA.
PI: Dr. Juan Rafael de la Haba Rodríguez

Neoadyuvancia con Letrozol y Palbociclib en pacientes con cáncer de mama estadíos II-IIIb, Fenotipo RH (+) / HER2 (-) y Recurrence Score (Oncotype-Dx) Intermedio (18-25) o Alto (>25) con análisis de cambios en el RS a la cirugía.
PI: Dr. Juan Rafael de la Haba Rodríguez

Estudio aleatorizado, multicéntrico, de grupos paralelos y de fase III, para comparar la eficacia de Arfolitixorin frente a Leucovorin en combinación con 5-fluorouracilo, oxaliplatino y Bevacizumab en pacientes con cáncer colorrectal avanzado.
PI: Dr. Mª José Ortiz Morales

Ensayo fase III, aleatorizado, abierto, multicéntrico e internacional para determinar la eficacia y la seguridad de durvalumab en combinación con gemcitabina + cisplatino como tratamiento neoadyuvante seguido de durvalumab en monoterapia como tratamiento.
PI: Dr. Mª José Méndez Vidal

Estudio de fase II para evaluar la eficacia de panitumumab + FOLFIRI en el tratamiento de segunda línea de pacientes con cáncer colorrectal metastásico con gen RAS nativo, inicialmente mutado, que habían recibido tratamiento estándar con FOLFOX/CAPOX + be.
PI: Dr. Enrique Aranda Aguilar

TRITON3: Estudio en fase III, multicéntrico, aleatorizado y abierto de rucaparib frente al tratamiento elegido por el médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado a una deficiencia en la recombinación homólo.
PI: Dr. Mª José Méndez Vidal

Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nu.
PI: Dr. Juan Rafael de la Haba Rodríguez

Ensayo clínico Fase II randomizado de quimioinmunoterapia neo-adyuvante versus quimioterapia sola para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado y potencialmente resecable.
PI: Dr. Isidoro Barneto Aranda

Ensayo clínico Fase II abierto de Atezolizumab en combinación con bevacizumab como primera línea de tratamiento para pacientes con carcinoma de pulmón no microcítico no escamoso localmente avanzado o metastásico seleccionados según carga mutacional tumora.
PI: Dr. Isidoro Barneto Aranda

Estudio de fase 2, abierto, de encorafenib + binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E.
PI: Dr. Isidoro Barneto Aranda

Ensayo clínico de fase II multicéntrico para evaluar la actividad del encorafenib y del binimetinib previo al tratamiento local en pacientes con melanoma BRAF mutado con metástasis cerebral.
PI: Dr. Pedro Sánchez Mauriño

A phase 3, open label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarc.
PI: Dr. Rosa Mª Rodríguez Alonso

Estudio en fase 2/3, abierto y aleatorizado de olaparib más pembrolizumab en comparación con quimioterapia más pembrolizumab después de inducción del beneficio clínico con quimioterapia de primera línea más pembrolizumab en participantes con cáncer de mam.
PI: Dr. Juan Rafael de la Haba Rodríguez

A RANDOMIZED DOUBLE-BLIND CONTROLLED PHASE 3 STUDY OF CABOZANTINIB IN COMBINATION WITH NOVOLUMAB AND IPLIMUMAB VERSUS NIVOLUMBAB AND IPLIMUMAB IN SUBJECTS WITH PREVIOSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK.
PI: Dr. Mª José Méndez Vidal

Multicenter prospective study of prognostic factors in prostate cancer resistant to castration treated with abiraterone.
PI: Dr. Mª José Méndez Vidal

Multicenter prospective study of prognostic factors in castration resistant treated with docetaxel or cabazitaxel prostate cancer.
PI: Dr. Mª José Méndez Vidal

 Clinical profile and therapeutic management of patients with pancreas cancer, Registry of Hospital Medical Oncology services in Spain.
PI: Dr. Enrique Aranda Aguilar

The T790M mutation detection technology by BEAMing in patients with NSCLC and EGFR mutated in stage IV. LUNGBEAM study.
PI: Dr. Isidoro Barneto Aranda

Evaluación clínica de OncoBEAM mediante el panel extendido de 34 mutaciones de RAS: Comparación de la determinación de la mutación RAS en ADN tumoral circulante y en muestra de tejido en pacientes con cáncer colorrectal metastático.
PI: Dr. Enrique Aranda Aguilar

Multi-centre observational prospective study on fatigue- and hand-foot syndrome-related quality of life in patients with metastatic renal cell carcinoma receiving a tyrosine kinase inhibitor as first-line treatment.
PI: Dr. Mª José Méndez Vidal

Prospective registry study in patients with unresectable locally advanced or metastatic breast cancer (MBC). RegistEM Study
PI: Dr. Juan Rafael de la Haba Rodríguez

Estudio prospectivo multicéntrico de factores pronósitcos en cáncer de próstata resistente a la castración tratados con RADIUM-223.
PI: Dr. Mª José Méndez Vidal

Retrospective observational study on the treatment of metastatic colorectal cancer (mCRC) in Spain.
PI: Dr. Enrique Aranda Aguilar

Estudio prospectivo multicéntrico de factores pronósitcos en cáncer de PROStata resistente a la castración tratados con RADIUM-223.
PI: Dr. Mª José Méndez Vidal

Estudio prospectivo multicéntrico de factores pronósticos en cáncer de PROStata resistente a la castración tratados con ENZAlutamida.
PI: Dr. Mª José Méndez Vidal

S-AVANT. Seguimiento del estudio avant hasta 8 y 10 años (mediana de seguimiento) en pacientes con carcinoma de colon.
PI: Dr. Enrique Aranda Aguilar

Estudio CODEPICUP: Estudio observacional, multicéntrico, propectivo en pacientes con cáncer de origen desconocido a los que se realiza el test de diagnóstico EPICUP.
PI: Dr. Rosa Mª Rodríguez Alonso

Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progresión tras quimioterapia basada en platino.
PI: Dr. Mª José Méndez Vidal

Estudio observacional retrospectivo del tratamiento con nab-paclitaxel en pacientes con cáncer de mama metastásico HER2-negativo en condiciones de práctica clínica habitual (estudio CAREMA).
PI: Dr. Juan Rafael de la Haba Rodríguez

Análisis retrospectivo de factores clínicos asociados a un mayor beneficio con Axitinib en Cáncer Renal metastásico (Estudio AXILONG).
PI: Dr. Mª José Méndez Vidal

Evaluación de la calidad de vida de pacientes con estreñimiento incluido por opioides en tratamiento con Naloxegol. Estudio de un año de seguimiento. ESTUDIO KYONAL.
PI: Dr. Pedro Sánchez Mauriño

Determinación del estado mutacional del RAS en biopsias líquidas de sujetos con cáncer colorrectal metastásico RAS no mutado en primera línea: estudio observervacional, prospectivo y multicéntrico en España (Estudia PERSEIDA).
PI: Dr. Manuel J  Valladares Ayerbes

Observational epidemiological study of cancer-associated thrombosis Registry of thrombosis and neoplasia of EOM/ Estudio observacional descriptivo sobre la trombosis asociada al cáncer. Registro de trombosis y neoplasias de la SEOM. Estudio TESEO.
PI: Dr. José Ortiz Morales

Estudio observacional retrospectivo de pacientes con tumores del estroma gastrointestinal (GIST), metastásico o localmente avanzado, tratado con sunitinib. Análisis exploratorio de factores pornósticos y predictivos en largos respondedores.
PI: Dr. Alberto Luis Moreno Vega

Análisis retrospectivo de la supervivicencia global en pacientes con cáncer colorrectal metastásico (CCM) en España: análisis retrospectivo extendido de RWD.
PI: Dr. Rosa Mª Rodríbuez Alonso

Efectividad de la dosis de 120 mg de lanreotida en pacientes con tumores neuroendocrinos pancreaticos (TNEP) localmente avanzados o metastásicos en la práctica clínica habitual.
PI: Dr. Raquel Serrano Blanch

ESTUDIO OBSERVACIONAL AMBISPECITVO DE REGISTRO DE EMBARAZO Y CANCER DE MAMA.
PI: Dr. Juan Rafael de la Haba Rodríguez

ESTUDIO DE LA EFICACIA Y SEGURIDAD DEL TRTAMIENTO CON CABOZANTINIB EN PACIENTES CON CARCINOMA DE CELULAS RENALES AVANZADO DENTRO DEL PROGRAMA ESPAÑOL DE USO COMPASIVO EN CODICIONES DE PRACTICA CLINICA REAL.
PI: Dr. Mª José Méndez Vidal

Members

Dr. Enrique Aranda Aguilar

Principal Investigator

Dr. Juan Rafael de la Haba Rodríguez

Co-Principal Investigator

Team

Juan Rafael de la Haba Rodríguez, Auxiliadora Gómez España, Antonio Martínez Peinado, Carlos Villar Pastor, Elena Fuentes Vaamonde, Isidoro Barneto Aranda, Mª Teresa Cano Osuna, Mª José Méndez Vidal, Ignacio Porras Quintela, Pedro Sánchez Mauriño, Raquel Serrano Blanch, Alberto Luis Moreno Vega, Laura María López Sánchez, Silvia Guil Luna, Cristina Morales Estévez, Manuel Jesús Valladares Ayerbes, Jon Peñarando Sáez, Rafael Mena Osuna, Mª José Ortiz Morales, Marta del Pilar Toledano Fonseca, Daniel José Campón Montilla, Mª Ángeles Diaz Diaz, Sonia Rodríguez de Julián, Isabel Jaraba Mezquida, Amalia Leña Barranco, María López García, Jacinta Marín Serrano, Mª Jose Marín Serrano, Mª Pilar Mesa Blanco, Rosario Miranda García